comparemela.com

Latest Breaking News On - Obstruction impact - Page 3 : comparemela.com

Positive Topline Results for SEQUOIA-HCM Trial in OHCM

Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.

China
Burlington
Massachusetts
United-states
Fadyi-malik
Martins-maron
Tufts-university-school-of-medicine
Drug-administration
Research-development
National-principal-investigator
National-medical-products-administration

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy -December 27, 2023 at 07:31 am EST

Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant.

United-states
China
Fadyi-malik
Diane-weiser
Martin-maron
Tufts-university-school-of-medicine
Exchange-commission
Us-food-drug-administration
Globenewswire-inc
Cytokinetics-incorporated-nasdaq
National-medical-products-administration
Cytokinetics-incorporated

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

27.12.2023 - Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant and Clinically Meaningful Improvements in All . Seite 1

Cytokinetics-incorporated-nasdaq
Company-to-host-conference-call
Treatment-interruptions-due
Host-conference-call
Webcast-today
Quantitative-understanding
Obstruction-impact
Cytokinetics-chart
Ytokinetics-kurs
Ytokinetics-aktie

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients…

SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) Cytokinetics, Incorporated CYTK today announced that members of its senior management will host…

Cytokinetics-incorporated
Quantitative-understanding
Obstruction-impact
News
Ggregator
Reaking-news
Uration
Media

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from ...

SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of its senior management will host an investor call at 8:30 AM

United-states
Diane-weiser
Journal-of-the-american-college-cardiology
Facebook
Symphony-health
Linkedin
Youtube
Corporate-communications
Cytokinetics-incorporated-nasdaq
Exchange-commission
Quantitative-understanding
Obstruction-impact

vimarsana © 2020. All Rights Reserved.